Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ross C. Donehower"'
Autor:
Mark Yarchoan, Chiung‐Yu Huang, Qingfeng Zhu, Anna K. Ferguson, Jennifer N. Durham, Robert A. Anders, Elizabeth D. Thompson, Noah S. Rozich, Dwayne L. Thomas II, Julie M. Nauroth, Christina Rodriguez, Arsen Osipov, Ana De Jesus‐Acosta, Dung T. Le, Adrian G. Murphy, Daniel Laheru, Ross C. Donehower, Elizabeth M. Jaffee, Lei Zheng, Nilofer S. Azad
Publikováno v:
Cancer Medicine, Vol 9, Iss 4, Pp 1485-1494 (2020)
Abstract Background Mismatch repair proficient (MMRp) colorectal cancer (CRC) has been refractory to single‐agent programmed cell death protein 1 (PD1) inhibitor therapy. Colon GVAX is an allogeneic, whole‐cell, granulocyte‐macrophage colony‐
Externí odkaz:
https://doaj.org/article/d4ba8200190f4f8999ae7ef37f32141a
Autor:
Cara Wilt, Jin He, Amy Ryan, Lei Zheng, Christi Walsh, Georgios Gemenetzis, Anne Marie Lennon, Dung T. Le, Vikesh K. Singh, Valerie Lee, Mouen A. Khashab, Eun Ji Shin, Lindsay Parish, Ding Ding, Chunhui Yuan, Daniel A. Laheru, Lindsey Manos, Elizabeth D. Thompson, Lara Groshek, Keith McIntyre, Dea Cunningham, Ross C. Donehower, Ana De Jesus-Acosta, Rachel Klein, John L. Cameron, Nilo Azad, Mary Hodgin, Alex B. Blair, Robert A. Anders, Elliot K. Fishman, Carol Judkins, Ammar A. Javed, William R. Burns, Jonathan Teinor, Amol Narang, Zunaira N. Javed, Richard A. Burkhart, Alison P. Klein, Adrian Murphy, Nicholas J. Roberts, Michael J. Wright, Christopher L. Wolfgang, Matthew J. Weiss, Elizabeth M. Jaffee, Amy Hacker-Prietz, Jun Yu, Atif Zaheer, Caitlin Brown, Ralph H. Hruban, Vincent P. Groot
Publikováno v:
Cancer letters
Recent research on genomic profiling of pancreatic ductal adenocarcinoma (PDAC) has identified many potentially actionable alterations. However, the feasibility of using genomic profiling to guide routine clinical decision making for PDAC patients re
Autor:
Lei Zheng, Dwayne L. Thomas, Elizabeth M. Jaffee, Dung T. Le, Julie M. Nauroth, Noah Rozich, Anna Ferguson, Nilofer S. Azad, Jennifer N. Durham, Ana De Jesus-Acosta, Mark Yarchoan, Ross C. Donehower, Arsen Osipov, Adrian Murphy, Robert A. Anders, Christina Rodriguez, Elizabeth D. Thompson, Daniel A. Laheru, Qingfeng Zhu, Chiung Yu Huang
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 4, Pp 1485-1494 (2020)
Cancer Medicine, Vol 9, Iss 4, Pp 1485-1494 (2020)
Background Mismatch repair proficient (MMRp) colorectal cancer (CRC) has been refractory to single‐agent programmed cell death protein 1 (PD1) inhibitor therapy. Colon GVAX is an allogeneic, whole‐cell, granulocyte‐macrophage colony‐stimulati
Autor:
Kevin C. Soares, Daniel A. Laheru, Ana De Jesus-Acosta, Nilofar Azad, Matthew J. Weiss, Lei Zheng, Nita Ahuja, Christopher L. Wolfgang, Yifei Sun, Amol Narang, Valerie Lee, Ross C. Donehower, Dung T. Le, Martin A. Makary, Adrian Murphy, Linda Chen, Avani S. Dholakia, Alex B. Blair, Chiung Yu Huang, Joseph M. Herman, Elliot K. Fishman, Bikram Shrestha, Luis A. Diaz, Tingbo Liang, Victoria M. Kim, Ralph H. Hruban, Lauren M. Rosati, Amy Hacker-Prietz, John L. Cameron, Farzana A. Faisal, Jin He
Publikováno v:
Cancer Medicine
The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic adenocarcinoma (BL‐PDAC) is increasing. However, the impact of neoadjuvant chemotherapy and radiation therapy on the outcome of BL‐PDAC remains to be elucidated
Autor:
Antonio Jimeno, Ross C. Donehower, Runyan Jin, Ping He, Wells A. Messersmith, Gretchen E. Taylor, W. Thomas Purcell, Arvind Dasari, Rosalind Walker, Daniel A. Laheru, Manuel Hidalgo, Michelle A. Rudek
Publikováno v:
Journal of Clinical Pharmacology
ABT‐751 is an orally bioavailable sulfonamide with antimitotic properties. A nonrandomized phase 1 dose‐escalation study of ABT‐751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab was conducted to define the maximum tol
Autor:
Sarita Dubey, Elwyn Loh, Min Zhu, Sameer Doshi, Rui Tang, Timothy Iveson, Yizhou Jiang, Kelly S. Oliner, Ross C. Donehower, Yilong Zhang
Publikováno v:
British Journal of Cancer
Background: Rilotumumab, an investigational, monoclonal antibody, inhibits MET-mediated signalling. In a randomized phase 2 trial of rilotumumab±epirubicin/cisplatin/capecitabine in gastric or oesophagogastric junction cancer, patients receiving ril
Autor:
Ross C. Donehower, Michael Torbenson, Kenzo Hirose, Nita Ahuja, Georgios Karagkounis, Timothy M. Pawlik, Michael A. Choti, Luis A. Diaz, Nilofer S. Azad, Hubert Darius J. Daniel
Publikováno v:
Cancer. 119:4137-4144
BACKGROUND Molecular biomarkers offer the potential for refining prognostic determinants in patients undergoing cancer surgery. Among patients with colorectal cancer, KRAS and BRAF are important biomarkers, but their role in patients undergoing surgi
Autor:
Wells A. Messersmith, Piotr Kulesza, Christine A. Iacobuzio-Donahue, Daniel A. Laheru, Michelle A. Rudek, Janet Dancey, Antonio Jimeno, Manuel Hidalgo, Ming Zhao, Michael A. Carducci, Yasmin Kahn, Heather A. Jacene, Alexander I. Spira, Ross C. Donehower
Publikováno v:
Clinical Colorectal Cancer. 9:297-304
This phase I study was conducted to determine the maximum tolerated dose (MTD) of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) in patients with advanced colorectal
Autor:
Thaddeus Beck, Hui-Ling Zhen, Nikhil Uppal, Safi Shahda, Daniel D. Von Hoff, Albert Assad, Julie Switzky, Ross C. Donehower, Steven J. Cohen, Gregory L. Beatty, Afshin Eli Gabayan
Publikováno v:
The Oncologist. 24:14-e10
Lessons Learned Itacitinib in combination with nab-paclitaxel plus gemcitabine demonstrated an acceptable safety profile with clinical activity in patients with advanced solid tumors including pancreatic cancer. The results support future studies of
Autor:
Michelle A. Rudek, Ignacio Garrido-Laguna, Christine A. Iacobuzio-Donahue, N. V. Rajeshkumar, Aik Choon Tan, Wen Wee Ma, M. Uson, Belen Rubio-Viqueira, Ming Zhao, Daniel A. Laheru, Antonio Jimeno, Ross C. Donehower, M C Villaroel, M. Angenendt, Michael T. Barrett, Manuel Hidalgo
Publikováno v:
British Journal of Cancer
Background: The purpose of this work was to determine the efficacy of inhibiting mammalian target of rapamycin (mTOR) in pancreatic cancer preclinical models and translate preclinical observations to the clinic. Methods: Temsirolimus (20 mg Kg−1 da